Xler8tr

xler8tr working with its strategic partners - some of the leading global advisory businesses and government funded bodies - believe that we have a solution that will reverse the trend of declining r&d; productivity suffered by the pharmaceutical industry. using xler8tr’s unique tool ‘xamn’, global pharmas can deep dive access an early stage ip portfolio of 30,000+ research projects worth £15bn, and growing by £1.4bn annually, that historically has not appeared on the radar. pharmas can now be pro-active in sourcing pre-incubation interesting science, adding much needed volume and diversity to their early stage pipeline without a drop in quality. too many incubations are currently failing due to non science (commercial) reasons, and at a starting price of £2m / incubation this lack of pre screening has a material effect on productivity. by using xler8tr, sponsoring pharma can stress test the commercials pre-incubation, weeding out probable failures at 1/20th of their current cost. pre-i